Carboxylic acids

Lannett Launches Fluvastatin Sodium ER Tablets

Retrieved on: 
Monday, July 12, 2021
Chemistry, Organic chemistry, Carboxylic acids, Physical sciences, Diols, Statins, Hepatotoxins, Fluvastatin, Indoles, Novartis, Tablet computer

PHILADELPHIA, July 12, 2021 /PRNewswire/ --Lannett Company, Inc. (NYSE: LCI) today announced that it recently began marketing Fluvastatin Sodium Extended-release Tablets, 80 mg, a partnered product.

Key Points: 
  • PHILADELPHIA, July 12, 2021 /PRNewswire/ --Lannett Company, Inc. (NYSE: LCI) today announced that it recently began marketing Fluvastatin Sodium Extended-release Tablets, 80 mg, a partnered product.
  • Total U.S. sales of Fluvastatin Sodium Extended-release Tablets, 80 mg, according to IQVIA market, were approximately $10 million for the 12 months ending May 2021, although actual generic market values are expected to be lower.
  • "Although the market potential is modest, we are pleased to offer an affordable Fluvastatin alternative to our customers," said Tim Crew, chief executive officer of Lannett.
  • "Currently, only one other competitor markets generic Fluvastatin Sodium Extended-release Tablets, 80 mg, in the U.S."
    Fluvastatin Sodium Extended-release Tablets, the generic equivalent of Novartis' Lescol XL Tablets, is used as an adjunct to diet to treat elevated cholesterol levels.

Hypertension in CKD Markets: Diuretics, RAS Blockade, B-Blockers, Calcium Channel Blockers - Global Size, Share, Outlook, and Opportunity Analysis, 2020-2021 & 2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 26, 2021
Health, Pharmaceutical, Chemical compounds, Antihypertensive agents, Drugs, Chemistry, Carboxylic acids, Combination drugs, Sacubitril/valsartan, Sacubitril, Valsartan, Novartis, Angiotensin II receptor blocker

The "Hypertension in CKD Market, by Drug Class, By Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hypertension in CKD Market, by Drug Class, By Distribution Channel, and by Region - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • For instance, in 2018, Novartis International AG announced positive results for Entresto (sacubitril/valsartan).
  • According to the clinical trials conducted by the company, it was found that Entresto (sacubitril/valsartan) helped to preserve kidney function in patients suffering from cardiovascular diseases.
  • The increasing number of patients undergoing dialysis treatment is expected to drive growth of the global hypertension in CKD market.

Aprea Therapeutics to Participate in the 2021 Oppenheimer Rare & Orphan Disease Summit

Retrieved on: 
Friday, May 21, 2021
Tumors of the hematopoietic and lymphoid tissues, Cancer, Protein kinase inhibitors, Bemcentinib, Carboxylic acids, ETV6

The Company\xe2\x80\x99s lead product candidate is eprenetapopt (APR-246), a small molecule in clinical development for hematologic malignancies and solid tumors.

Key Points: 
  • The Company\xe2\x80\x99s lead product candidate is eprenetapopt (APR-246), a small molecule in clinical development for hematologic malignancies and solid tumors.
  • APR-548, a next generation small molecule reactivator of mutant p53, is being developed for oral administration.
  • Pre-clinical anti-tumor activity has been observed with eprenetapopt in a wide variety of solid and hematological cancers, including MDS, AML, and ovarian cancer, among others.
  • We undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.\n'

Aprea Therapeutics to Participate in the 2021 RBC Capital Markets Global Healthcare Conference

Retrieved on: 
Tuesday, May 18, 2021
Tumors of the hematopoietic and lymphoid tissues, Cancer, Protein kinase inhibitors, Bemcentinib, Carboxylic acids, ETV6

The Company\xe2\x80\x99s lead product candidate is eprenetapopt (APR-246), a small molecule in clinical development for hematologic malignancies and solid tumors.

Key Points: 
  • The Company\xe2\x80\x99s lead product candidate is eprenetapopt (APR-246), a small molecule in clinical development for hematologic malignancies and solid tumors.
  • APR-548, a next generation small molecule reactivator of mutant p53, is being developed for oral administration.
  • Pre-clinical anti-tumor activity has been observed with eprenetapopt in a wide variety of solid and hematological cancers, including MDS, AML, and ovarian cancer, among others.
  • We undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.\n'

New Real-World Observational Analysis of UPTRAVI® (selexipag) Underscores the Importance of Risk Assessment for Treating Pulmonary Arterial Hypertension (PAH) Patients

Retrieved on: 
Tuesday, April 6, 2021
Chemistry, Chemical compounds, Organic compounds, Carboxylic acids, Hypertension, Prostaglandins, Secondary alcohols, Sulfonamides, Pulmonary hypertension, Selexipag, Prostacyclin, Riociguat

In the pivotal GRIPHON trial, UPTRAVI was proven to reduce the risk of disease progression by 40%.

Key Points: 
  • In the pivotal GRIPHON trial, UPTRAVI was proven to reduce the risk of disease progression by 40%.
  • SPHERE enrolled patients who were either newly initiated on UPTRAVI (60 days before enrollment) or previously received UPTRAVI with documentation of dose titration at study enrollment.
  • The efficacy of UPTRAVI in PAH was established in GRIPHON (Prostacyclin [PGI2] Receptor agonist In Pulmonary arterial HypertensiON), the largest randomized, controlled trial ever conducted in PAH patients.
  • Hyperthyroidism was observed in 1% (n=8) of patients on UPTRAVI and in none of the patients on placebo.

FDA Approves Althera's Roszet (rosuvastatin and ezetimibe) Tablets, a New Oral Therapy for Powerful Cholesterol Reduction

Retrieved on: 
Wednesday, March 31, 2021
Drugs, Chemical compounds, Chemistry, Statins, Carboxylic acids, Diols, Hepatotoxins, Cholesterol absorption inhibitor, Rosuvastatin, Ezetimibe, Low-density lipoprotein, Cholesterol

Roszet contains rosuvastatin, a powerful statin for LDL-C reduction, and ezetimibe, an efficacious cholesterol absorption inhibitor.

Key Points: 
  • Roszet contains rosuvastatin, a powerful statin for LDL-C reduction, and ezetimibe, an efficacious cholesterol absorption inhibitor.
  • Rosuvastatin and ezetimibe have been extensively studied in combination therapy and have been shown to significantly reduce LDL cholesterol beyond the statin alone.
  • Combination therapy has been widely used in hypertension to achieve lower blood pressure targets.
  • Althera is continuing to work with all stakeholders to ensure that Roszet is affordable and accessible to all.

Saroglitazar Mg: A Potent and Selective Peroxisome Proliferator-activated Receptor Alpha and Gamma Dual Agonist - Global Emerging Insight and Market Forecast 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, March 16, 2021
Health, Pharmaceutical, Branches of biology, Carboxylic acids, Transcription factors, Intracellular receptors, Cell biology, Chemistry, Peroxisome proliferator-activated receptor alpha, Saroglitazar, Peroxisome proliferator-activated receptor, PPARGC1B, Alpha agonist

The "Saroglitazar Mg - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Saroglitazar Mg - Emerging Insight and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • SAROGLITAZAR Mg is a potent and selective peroxisome proliferator-activated receptor alpha and gamma dual agonist.
  • "SAROGLITAZAR Mg - Emerging Insight and Market Forecast - 2030" the report provides comprehensive insights about an investigational product for Primary Biliary Cirrhosis in 7 Major Markets.
  • Further, it also consists of future market assessments inclusive of the market forecast, SWOT analysis, market competitors, and other emerging therapies.

What Does Construction Recovery Mean for Polyaspartic Coatings Demand? Fact.MR Study Reveals

Retrieved on: 
Friday, March 12, 2021
Chemistry, Carboxylic acids, Physical sciences, Plastics, Business process, Materials science, Polyaspartic, Polymers, Market research, Aspartic acid, Coating

Fact.MR, in its new offering, presents a detailed analysis of the global polyaspartic coatings market.

Key Points: 
  • Fact.MR, in its new offering, presents a detailed analysis of the global polyaspartic coatings market.
  • Which are the major companies leading the global polyaspartic coatings market?
  • Container glass coatings Market : Explore Fact.MR's container glass coatings market research report, offering a detailed study on multiple market trends for the present and upcoming decade.
  • Release coatings Market : The global release coatings market report by Fact.MR delivers a detailed analysis on the strategies and competitive landscape for the upcoming period.

What Does Construction Recovery Mean for Polyaspartic Coatings Demand? Fact.MR Study Reveals

Retrieved on: 
Friday, March 12, 2021
Chemistry, Carboxylic acids, Physical sciences, Plastics, Business process, Materials science, Polyaspartic, Polymers, Market research, Aspartic acid, Coating

Fact.MR, in its new offering, presents a detailed analysis of the global polyaspartic coatings market.

Key Points: 
  • Fact.MR, in its new offering, presents a detailed analysis of the global polyaspartic coatings market.
  • Which are the major companies leading the global polyaspartic coatings market?
  • Container glass coatings Market : Explore Fact.MR's container glass coatings market research report, offering a detailed study on multiple market trends for the present and upcoming decade.
  • Release coatings Market : The global release coatings market report by Fact.MR delivers a detailed analysis on the strategies and competitive landscape for the upcoming period.

Novartis Entresto® granted expanded indication in chronic heart failure by FDA

Retrieved on: 
Tuesday, February 16, 2021
Antihypertensive agents, Medical specialties, Clinical medicine, Drugs, Carboxylic acids, Sacubitril/valsartan, Heart failure, Valsartan, Sacubitril, Neprilysin, Angiotensin II receptor blocker, Angiotensin

FortiHFy includes trials across the spectrum of heart failure, such as PARADIGM-HF, PIONEER-HF, TRANSITION, PROVE-HF, PARAGON-HF and PARAMOUNT.

Key Points: 
  • FortiHFy includes trials across the spectrum of heart failure, such as PARADIGM-HF, PIONEER-HF, TRANSITION, PROVE-HF, PARAGON-HF and PARAMOUNT.
  • Entresto (sacubitril/valsartan) is a prescription medicine to treat adults with long-lasting (chronic) heart failure to help reduce the risk of death and hospitalization.
  • Patients should talk to their doctor about other ways to treat heart failure if they plan to become pregnant.
  • 2010;303(21):2141-2147. doi:10.1001/jama.2010.748
    Langenickel T, Dole W. Angiotensin receptor-neprilysin inhibition with LCZ696: a novel approach for the treatment of heart failure.